Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.59 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.50 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896913 | 0.82 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1MBTD1ALDH1A1MEN1 | |
| SCHEMBL15131501 | 0.81 | L3MBTL3 (0.65) | L3MBTL3L3MBTL1MBTD1ALDH1A1MEN1 | |
| SCHEMBL10194872 | 0.81 | L3MBTL3 (0.65) | L3MBTL3L3MBTL1MBTD1ALDH1A1MEN1 | |
| SCHEMBL17888405 | 0.78 | ALDH1A1 (0.64) | L3MBTL3L3MBTL1MBTD1ALDH1A1MEN1 | |
| SCHEMBL19226622 | 0.78 | KMT2A (0.61) | L3MBTL3L3MBTL1MBTD1ALDH1A1MEN1 | |
| SCHEMBL15317728 | 0.78 | MEN1 (0.61) | L3MBTL3L3MBTL1MBTD1ALDH1A1MEN1 | |
| SCHEMBL17076779 | 0.77 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1MBTD1ALDH1A1MEN1 | |
| SCHEMBL17888368 | 0.77 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1MBTD1ALDH1A1MEN1 | |
| SCHEMBL3060695 | 0.76 | CA12 (0.68) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL394640 | 0.75 | LRRK2 (0.57) | L3MBTL3L3MBTL1ALDH1A1MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382191-B1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE BAHAMAS LTD (BS) | 2014-11-12 | — | — | EP | disclosed |
| US-8741899-B2 | (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8101614-B2 | Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | L3MBTL3 2063/4885L3MBTL1 1498/4885MBTD1 945/4885 |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | L3MBTL3 2063/4885L3MBTL1 1498/4885MBTD1 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.